Biomarkers for Preclinical Research
Our multiplexed immunoassay biomarker testing services are ideal for preclinical research, due to our ability to measure more than a hundred biomarkers cost- effectively using a small volume of sample..
- Our Rodent MAPs (Multi-Analyte Profiles) closely mirror our Human MAPs, and because the assays are performed on the same clinically-validated platform, you receive consistent and meaningful analysis when translating studies from rodents to primates.
- We can create CustomMAPs to provide you with a more cost-effective solution based on a focused set of biomarkers.
- We offer the most comprehensive collection of quantitative biomarkers for use in drug development. We believe in "Casting a Wide Net" to identify biomarker patterns earlier in the development process. This offers significant cost savings. We call this the 'RBM Approach,' and it drives everything we do. Listen to a 3-minute podcast about the RBM Approach, given by our VP Strategic Development, Dr. Ralph McDade.
- Unexpected drug-induced renal toxicity is a leading cause of failure in drug development programs. Investigators have been limited by biomarkers that lack the sensitivity necessary to identify damage before it becomes permanent. In cooperation with Novartis and the Predictive Safety Testing Consortium, we have developed KidneyMAP panels that provides sensitive detection and quantitation of kidney damage. RBM's Rat & Human KidneyMAP panels enable drug developers to efficiently prioritize medicinal chemistry programs and accelerate decisions on preclinical and clinical trial protocols.
Our laboratory's quality standards and MAP validation process are at the heart of every test we run, every time. Please contact us at info@rulesbasedmedicine.com for additional information.
